Drug Profile

ISM 0676

Alternative Names: ISM-0676

Latest Information Update: 24 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator InSilico Medicine
Class Antihyperglycaemics; Obesity therapies; Small molecules
Mechanism of Action Gastric inhibitory polypeptide receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

24 Apr 2026 ISM 0676 is available for licensing as of 24 Apr 2026. https://insilico.com/pipeline
29 Jan 2026 Preclinical trials in Obesity in USA (PO), prior to January 2026
29 Jan 2026 Preclinical trials in Type 2 diabetes mellitus in USA (PO), prior to January 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com